Discriminative stimulus and subjective effects of opioids with mu and kappa activity: Data from laboratory animals and human subjects

Psychopharmacology

Volumn 130, Issue 1, 1997, Pages 14-27

  Dykstra, Linda A ^a   Preston, Kenzie L ^b,c   Bigelow, George E ^c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Discriminative stimulus; Humans; Opioids

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; BREMAZOCINE; BUTORPHANOL; CODEINE; CYCLAZOCINE; ENADOLINE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ETORPHINE; FENTANYL; HYDROMORPHONE; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; METHADONE; MORPHINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; NALBUPHINE; NALORPHINE; OPIATE RECEPTOR; PENTAZOCINE; SPIRADOLINE;

ANIMAL MODEL; DISCRIMINATIVE STIMULUS; DRUG CLASSIFICATION; DRUG DISCRIMINATION; EXPERIMENTAL ANIMAL; HUMAN; METHODOLOGY; MOOD; NONHUMAN; PRIORITY JOURNAL; REVIEW; SPECIES DIFFERENCE; SUBSTANCE ABUSE;

ANIMALS; DISCRIMINATION (PSYCHOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MORPHINE; NALORPHINE; NARCOTICS; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU;

EID: 0031034889     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050208     Document Type: Review

References (79)

1. 2 analysis. J Pharmacol Exp Ther 243:591-597
2. Bickel WK, Bigelow GE, Preston KL, Liebson IA (1989) Opioid drug discrimination in humans: stability, specificity, and relation to self-reported drug effect. J Pharmacol Exp Ther 251: 1053-1063
3. Bigelow GE, Preston KL (1996) Opioid agonist-antagonist drug discrimination in humans following butorphanol-saline training. Problems of Drug Dependence, 1995, Proceedings of the 57th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc. NIDA Research Monograph, 162:344. NIH 96-4116, Department of Health and Human Services, Washington, D.C.
4. Brandt MR, France CP (1996) Discriminative stimulus effects of enadoline in pigeons. J Pharmacol Exp Ther 277:960-967
5. Butelman ER, Winger G, Zernig G, Woods JH (1995) Butorphanol: characterization of agonist and antagonist effects in rhesus monkeys. J Pharmacol Exp Ther 272:845-853
6. Chen JC, Smith ER, Cahill M, Cohen R, Rishman JB (1992) The opioid receptor binding of dezocine, morphine, fentanyl, butorphanol, and nalbupine. Life Sci 52:389-396
7. Craft RM, Dykstra LA (1990) Differential cross-tolerance to opioids in squirrel monkeys responding under a shock titration schedule. J Pharmacol Exp Ther 252:945-952
8. Dykstra LA (1990) Butorphanol, levallorphan, nalbuphine and nalorphine as antagonists in the squirrel monkey. J Pharmacol Exp Ther 254:245-252
9. Dykstra LA, Massie CA (1988) Antagonism of the analgesic effects of mu and kappa opioid agonists in the squirrel monkey. J Pharmacol Exp Ther 246:813-821
10. Dykstra LA, Gmerek DE, Winger G, Woods JH (1987a) Kappa opioids in rhesus monkeys. I. Diuresis, sedation, analgesia and discriminative stimulus effects. J Pharmacol Exp Ther 242: 413-420
11. Dykstra LA, Gmerek DE, Winger G, Woods JH (1987b) Kappa opioids in rhesus monkeys. II. Analysis of the antagonistic, actions of quadazocine and β-funaltrexamine. J Pharmacol Exp Ther 242:421-427
12. 2 analysis. In: Colpaert FC, Balster RL (eds) Transduction mechanisms of drug stimuli. Springer, Berlin, pp 107-121
13. Evans CJ, Keith DE Jr, Morrison H, Magendzo K, Edwards RH (1992) Cloning of a delta opioid receptor by functional expression. Science 258:1952-1955
14. Gerak LR, France CP (1996) Discriminative stimulus effects of nalbuphine in rhesus monkeys. J Pharmacol Exp Ther 276:523-531
15. Gerak LR, Butelman ER, Woods JH, France CP (1994) Antinociceptive and respiratory effects of nalbuphine in rhesus monkeys. J Pharmacol Exp Ther 271:993-999
16. Gmerek DE, Dykstra LA, Woods JH (1987) Kappa opioids in rhesus monkeys. III. Dependence associated with chronic administration. J Pharmacol Exp Ther 242:428-436
17. Haertzen CA (1970) Subjective effects of narcotic antagonists cyclazocine and nalorphine on the Addiction Research Center Inventory (ARCI). Psychopharmacologia 18:366-377
18. Hein DW, Young AM, Herling S, Woods JH (1981) Pharmacological analysis of the discriminative stimulus characteristics of ethylketazocine in the rhesus monkey. J Pharmacol Exp Ther 218:7-15
19. Holtzman SG, Cook L, Steinfels GF (1991) Discriminative stimulus effects of spiradoline, a kappa-opioid agonist. Psychopharmacology 105:447-452
20. Howell LL, Bergman J, Morse WH (1988) Effects of levorphanol and several kappa-selective opioids on respiration and behavior in rhesus monkeys. J Pharmacol Exp Ther 245:364-372
21. Jasinski DR (1977) Assessment of the abuse potentiality of morphine-like drugs (methods used in man). In: Martin WP (ed) Handbook of experimental pharmacology, vol 45. Springer, New York, pp 197-258
22. Jasinski DR, Mansky PA (1972) Evaluation of nalbuphine for abuse potential. Clin Pharmacol Ther 13:78-90
23. Jasinski DR, Preston KL (1986) Comparison of intravenously administered methadone, morphine and heroin. Drug Alcohol Depend 17:301-310
24. Jasinski DR, Martin WR, Hoeldtke RD (1970) Effects of short-and long-term administration of pentazocine in man. Clin Pharmacol Ther 11:385-403
25. Jasinski DR, Griffith JD, Pevnick JS, Clark SC (1975) Progress report on studies from the clinical pharmacology section of the Addiction Research Center. In: Problems of Drug Dependence 1975, Proceedings of the Committee on Problems of Drug Dependence, National Academy of Sciences, Washington, D.C., pp 121-161
26. Kieffer BL, Befort K, Gaveriaux-Ruff C, Hirth CG (1992) The 5-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. Proc Natl Acad Sci USA 89:12048-12052
27. Koek W, Woods JR (1989) Partial generalization in pigeons trained to discriminate morphine from saline: applications of receptor theory. Drug Dev Res 16:169-181
28. Kumor KM, Haertzen CA, Johnson RE, Kocher T, Jasinski D (1986) Human psychopharmacology of ketocyclazocine as compared with cyclazocine, morphine and placebo. J Pharmacol Exp Ther 238:960-968
29. Leander JD (1983a) A kappa opioid effect: increased urination in the rat. J Pharmacol Exp Ther 224:89-94
30. Leander JD (1983b) Evidence that nalorphine, butorphanol and oxilorphan are partial agonists at a κ-opioid receptor. Eur J Pharmacol 86:467-470
31. Leslie FM (1987) Methods used for the study of opioid receptors. Pharmacol Rev 39:197-249
32. Liguori A, Morse WH, Bergman J (1996) Respiratory effects of opioid full and partial agonists in rhesus monkesy. J Pharmacol Exp Ther 277:462-472
33. Lord JAH, Waterfield AA, Hughes J, Kosterlitz HW (1977) Endogenous opioid peptides: multiple agonists and receptors. Nature 267:495-499
34. Martin WR (1983) Pharmacology of opioids. Pharmacol Rev 35:283-323
35. Martin WR, Fraser HF (1961) A comparative study of physiological and subjective effects of heroin and morphine administered intravenously in postaddicts. J Pharmacol Exp Ther 133:388-399
36. Martin WR, Fraser HF, Gorodetsky CW, Rosenberg DE (1965) Studies of the dependence-producing potential of the narcotic antagonist 2-cyclopropylmethyl-2′-hydroxy-5,9-dimethy1-6,7-benzomorphan (cyclazocine, WIN 20,740, ARC II-c-3). J Pharmacol Exp Ther 150:426-436
37. Martin WR, Jasinski DR, Haertzen CA, Kay DC, Jones BE, Mansky PS, Carpenter RW (1973) Methadone - a reevaluation. Arch Gen Psychiatry 28:286-295
38. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE (1976) The effects of morphine- and nalorphine-like drugs in the non-dependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 197:517-532
39. Negus SS, Picker MJ, Dykstra LA (1990) Interactions between mu and kappa opioid agonists in the rat drug discrimination procdure. Psychopharmacology 102:465-473
40. Peters GR, Ward NJ, Antal EG, Lai PY, deMaar EW (1987) Diuretic actions in man of a selective kappa opioid agonist. U-62,066E. J Pharmacol Exp Ther 240:128-131
41. Pfeifer A, Brantl V, Herz A, Emrich HM (1986) Psychotomimesis mediated by k opiate receptors. Science 233:774-776
42. Picker MJ (1994) Kappa agonist and antagonist properties of mixed action opioids in a pigeon drug discrimination procedure. J Pharmacol Exp Ther 268:1190-198
43. Picker MJ, Dykstra LA (1987) Comparison of the discriminative stimulus properties of U50,488 and morphine in pigeons. J Pharmacol Exp Ther 243:938-945
44. Picker MJ, Dykstra LA (1989) Discriminative stimulus effects of mu and kappa opioids in the pigeon: analysis of the effects of full and partial mu and kappa agonists. J Pharmacol Exp Ther 249:557-566
45. Picker MJ, Doty P, Negus SS, Mattox SR, Dykstra LA (1990a) Discriminative stimulus properties of U50,488 and morphine: effects of training dose on stimulus substitution patterns produced by mu and kappa opioid agonists. J Pharmacol Exp Ther 254:13-22
46. Picker MJ, Yabrough J, Hughes CE, Smith MA, Morgan D, Dykstra LA (1993) Agonist and antagonist effects of mixed action opioids in the pigeon drug discrimination procedure: influence of training dose, intrinsic efficacy and interanimal differences. J Pharmacol Exp Ther 266:756-767
47. Picker MJ, Benyas S, Horwitz JA, Thompson K, Mathewson C, Smith MA (1996) Discriminative stimulus effects of butorphanol: influence of training dose on the substitution patterns produced by mu, kappa and delta opioids. J Pharmacol Exp Ther 279:1130-1141
48. Portoghese PS, Larson DD, Sayre LM, Fries DS, Takemori AE (1980) A novel opioid receptor site directed alkylating agent with irreversible nacrotic antagonistic and reversible agonistic activities. J Med Chem 23:233-234
49. Preston KL, Bigelow GE (1993) Differential naltrexone antagonism of hydromorphone and pentazocine effects in human volunteers. J Pharmacol Exp Ther 264:813-823
50. Preston KL, Bigelow GE (1994) Drug discrimination assessment of agonist/antagonist opioids in humans: a three-coice saline-hydromorphone-butorphanol procedure. J Pharmacol Exp Ther 271:48-60
51. Preston KL, Bigelow GE, Bickel WK, Liebson IA (1987) Three-choice drug discrimination in opioid-dependent humans: hydromorphone, naloxone and saline. J Pharmacol Exp Ther 243:1002-1009
52. Preston KL, Bigelow GE, Bickel WK, Liebson IA (1989) Drug discrimination in human post-addicts: agonist-antagonist opioids. J Pharmacol Exp Ther 250:184-196
53. Preston KL, Bigelow GE, Liebson IA (1990) Discriminative stimulus properties of naloxone, butorphanol, nalbuphine, and hydromorphone in opioid-dependent humans. Pharmacol Biochem Behav 37:511-522
54. Preston KL, Liebson IA, Bigelow GE (1992) Discrimination of agonist-antagonist opioids in humans trained on a two-choice saline-hydromorphone discrimination. J Pharmacol Exp Ther 261:62-71
55. Reisine T, Pasternak G (1996) Opioid Analgesics and Antagonists. In: Hardman JG; Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds) Goodman & Gilman's the pharmacological basis of therapeutics. McGraw-Hill, New York, pp 521-555
56. Schaefer GJ, Holtzman SG (1981) Morphine-like stimulus effects in the monkey: opioids with antagonist properties. Pharmacol Biochem Behav 14:241-245
57. Schmauss C, Yaksh TL (1984) In vivo studies on spinal opiate receptor systems mediating antinociception. II. Pharmacological profiles suggesting a differential association of mu, delta and kappa receptors with visceral chemical and cutaneous thermal stimuli in the rat. J Pharmacol Exp Ther 228:1-12
58. Shannon HE, Holtzman SG (1976) Evaluation of the discriminative effects of morphine in the rat. J Pharmacol Exp Ther 198:54-65
59. Shannon HE, Holtzman SG (1979) Morphine training dose: a determinant of stimulus generalization in the rat. Psychopharmacology 61:239-244
60. Shippenberg TS, Bals-Kubik R, Herz A (1987) Motivational properties of opioids; evidence that an activation of δ-receptors mediates reinforcement processes. Brain Res 436:234-239
61. Smith MA, Picker MJ (1995) Examination of the kappa agonist and antagonist properties of opioids in the rat drug discrimination procedure: influence of training dose and intrinsic efficacy. Behav Pharmacol 6:703-717
62. Teal JJ, Holtzman SG (1980) Discriminative stimulus effects of cyclazoine in the rat. J Pharmacol Exp Ther 212:368-376
63. Von Voitlander PF, Lahti RA, Ludens JH (1983) U-50,488: a selective and structurally novel non-mu (kappa) opioid agonist. J Pharmacol Exp Ther 224:7-12
64. Walker EA, Young AM (1993) Discriminative-stimulus effects of the low efficacy mu agonist nalbuphine. J Pharmacol Exp Ther 267:322-330
65. 2 analysis for naltrexone antagonism of discriminative stimulus and analgesic effects of opiate agonists in rats. J Pharmacol Exp Ther 271:959-968
66. Wang JB, Imai Y, Eppler CM, Gregor P, Spivak CE, Uhl GR (1993) μ opiate receptor: cDNA cloning and expression. Proc Natl Acad Sci USA 90:10230-10234
67. White JM, Holtzman SG (1981) Three-choice drug discrimination in the rat: morphine, cylazocine and saline. J Pharmacol Exp Ther 217:254-262
68. White JM, Holtzman SG (1982) Properties of pentazocine as a discriminative stimulus in the squirrel monkey. J Pharmacol Exp Ther 223:396-401
69. White JM, Holtzman SG (1983) Further characterization of the three-choice morphine, cyclazocine and saline discrimination paradigm: opioids with agonist and antagonist properties. J Pharmacol Exp Ther 224:95-99
70. Wikler A, Fraser HF, Isbell H (1953) N-Allylnormorphine: effects of single doses and precipitation of acute "abstinence syndromes" during addiction to morphine, methadone or heroin in man (post-addicts). J Pharmacol Exp Ther 109:8-20
71. Woods JH, Gmerek DE (1985) Substitution and primary dependence studies in animals. Drug Alcohol Depend 14:233-247
72. Woods JH, Winger G (1987) Opioids, receptors and abuse liability. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 1555-1564
73. Yasuda K, Raynor K, Kong H, Breder CD, Takeda J, Reisine T, Bell GI (1993) Cloning and functional comparison of κ and δ opioid receptors from mouse brain. Proc Natl Acad Sci USA 90:6736-6740
74. Young AM (1991) Discriminative stimulus profiles of psychoactive drugs. In: Mello N (ed) Adv Subst Abuse 4:139-203
75. Young AM, Stephens KR, Hein DW, Woods JH (1984) Reinforcing and discriminative stimulus properties of mixed agonist-antagonist opioids. J Pharmacol Exp Ther 229:118-126
76. Young AM, Walton MA, Perkins AN (1989) Characteristics of a discrimination among two doses of morphine and saline in pigeons. Drug Dev Res 16:163-168
77. Young AM, Masaki MA, Geula C (1992) Discriminative stimulus effects of morphine: effects of training dose on agonist and antagonist effects of mu opioids. J Pharmacol Exp Ther 261: 246-257
78. Zacny JP, Lichtor JL, Thapar P, Coalson DW, Flemming D, Thompson WK (1994) Comparing the subjective, psychomotor and physiological effects of intravenous butorphanol and morphine in healthy volunteers. J Pharmacol Exp Ther 270: 579-588
79. Zimmerman DM, Leander JD, Reel JK, Hynes MD (1987) Use of β-funaltrexamine to determine mu opioid receptor involvement in the analgesic activity of various opioid ligands. J Pharmacol Exp Ther 241:374-378